Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer

References

• American Cancer SocietyCancer Facts and Figures 2017AtlantaAmerican Cancer Society2017
   Google Scholar
• AlvarezRDMatulonisUAHerzogTJColemanRLMonkBJMarkmanMMoving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancerGynecol Oncol2016141340540927049967
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineECombePRecurrent ovarian cancerAnn Oncol201627suppl 1i63i6527141075
   PubMedGoogle Scholar
• ScottCLSwisherEMKaufmannSHPoly (ADP-ribose) polymerase inhibitors: recent advances and future developmentJ Clin Oncol201533121397140625779564
   PubMed Web of Science ®Google Scholar
• IhnenMzu EulenburgCKolarovaTTherapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancerMol Cancer Ther20131261002101523729402
   PubMed Web of Science ®Google Scholar
• KonecnyGEKristeleitRSPARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsBr J Cancer2016115101157117327736844
   PubMed Web of Science ®Google Scholar
• GundersonCCMooreKNOlaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancerFuture Oncol201511574775725757679
   PubMedGoogle Scholar
• PenningtonKPSwisherEMHereditary ovarian cancer: beyond the usual suspectsGynecol Oncol2012124234735322264603
   PubMed Web of Science ®Google Scholar
• PenningtonKPWalshTHarrellMIGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasClin Cancer Res201420376477524240112
   PubMed Web of Science ®Google Scholar
• KonstantinopoulosPACeccaldiRShapiroGID’AndreaADHomologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancerCancer Discov20155111137115426463832
   PubMed Web of Science ®Google Scholar
• CraftonSMBixelKHaysJLPARP inhibition and gynecologic malignancies: a review of current literature and on-going trialsGynecol Oncol2016142358859627168003
   PubMedGoogle Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialLancet Oncol201415885286124882434
   PubMed Web of Science ®Google Scholar
• BryantHESchultzNThomasHDSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature2005434703591391715829966
   PubMed Web of Science ®Google Scholar
• FarmerHMcCabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• KaufmanBShapira-FrommerRSchmutzlerRKOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationJ Clin Oncol201533324425025366685
   PubMed Web of Science ®Google Scholar
• DomchekSMAghajanianCShapira-FrommerREfficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapyGynecol Oncol2016140219920326723501
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerN Engl J Med2012366151382139222452356
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineELedermannJPensonRTreatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 studyPaper presented at: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer2017National Harbor, MD
   Google Scholar
• MirzaMRMonkBJHerrstedtJNiraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancerN Engl J Med2016375222154216427717299
   PubMed Web of Science ®Google Scholar
• SwisherEMLinKKOzaAMRucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialLancet Oncol2017181758727908594
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinomaNature2011474735360961521720365
   PubMed Web of Science ®Google Scholar
• MarquardAMEklundACJoshiTPan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugsBiomark Res20153926015868
   PubMedGoogle Scholar
• MoschettaMGeorgeAKayeSBBanerjeeSBRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancerAnn Oncol20162781449145527037296
   PubMed Web of Science ®Google Scholar
• FreyMKPothuriBHomologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literatureGynecol Oncol Res Pract20174428250960
   PubMedGoogle Scholar
• MatulonisUAPensonRTDomchekSMOlaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyAnn Oncol20162761013101926961146
   PubMed Web of Science ®Google Scholar
• JennerZBSoodAKColemanRLEvaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapyFuture Oncol201612121439145627087632
   PubMed Web of Science ®Google Scholar
• WahlbergEKarlbergTKouznetsovaEFamily-wide chemical profiling and structural analysis of PARP and tankyrase inhibitorsNat Biotechnol201230328328822343925
   PubMed Web of Science ®Google Scholar
• ThomasHDCalabreseCRBateyMAPreclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trialMol Cancer Ther20076394595617363489
   PubMed Web of Science ®Google Scholar
• DrewYMulliganEAVongWTTherapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2J Natl Cancer Inst2011103433434621183737
   PubMedGoogle Scholar
• United States Product Insert2017 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdfAccessed March 3, 2017
   Google Scholar
• PlummerRJonesCMiddletonMPhase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumorsClin Cancer Res200814237917792319047122
   PubMed Web of Science ®Google Scholar
• KristeleitRSBurrisHALoRussoPPhase I/II study of oral rucaparib: final phase I resultsJ Clin Oncol201432suppl 5 abstr2573
   Google Scholar
• Shapira-FrommerROzaAMDomcheckSMA Phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutationJ Clin Oncol201533 abstr5513
   PubMedGoogle Scholar
• KristeleitRSClinical activity of the Poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib in patients with high-grade ovarian carcinoma and a BRCA mutation: analysis of pooled data from study 10 (Parts 1, 2a, and 3) and ARIEL2 (Parts 1 and 2)Ann Oncol201627suppl 6856O26884590
   PubMedGoogle Scholar
• McCormickASwaislandHIn vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparibXenobiotica147 Epub20161026
   Google Scholar
• KikuchiRLaoYBowDAPrediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)J Pharm Sci2013102124426443224122511
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LYNPARZA (olaparib) capsules [prescribing information]Wilmington2016
   Google Scholar
• Clovis Oncology Rubraca (rucaparib) tablets [prescribing information]Boulder2016
   Google Scholar
• OakninAOzaAVTinkerIIntegrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC)Eur J Cancer201772suppl 1S95
   PubMedGoogle Scholar
• SwisherEMMcNeishIAColemanRLARIEL 2/3: an integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of responseJ Clin Oncol20143215 suppl abstrTS5619
   PubMedGoogle Scholar
• ClinicalTrials.govA Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Available from: https://clinicaltrials.gov/ct2/show/study/NCT02855944?term=ARIEL+4&rank=1. NLM identifier: NCT02855944Accessed January 29, 2017
   Google Scholar
• FramptonGMFichtenholtzAOttoGADevelopment and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNat Biotechnol201331111023103124142049
   PubMed Web of Science ®Google Scholar
• LinKKSunLMaloneySQuantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparibEur J Cancer201551suppl 3S531S532
   Google Scholar
• BouwmanPJonkersJMolecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?Clin Cancer Res201420354054724270682
   PubMed Web of Science ®Google Scholar
• LinKKSecondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancerEur J Cancer201669suppl 1S13
   Google Scholar
• McCormickADonoghuePDixonMOvarian cancers harbour defects in non-homologous end joining resulting in resistance to rucaparibClin Cancer Res20172382050206027702817
   PubMed Web of Science ®Google Scholar
• JiaoSXiaWYamaguchiHPARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppressionClin Cancer Res Epub201726
   Google Scholar
• Clovis OncologyA Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3) Available from https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&rank=1. NLM identifier: NCT01968213Accessed May 31, 2016
   Google Scholar